Drug profile · INN
cemiplimab
LIBTAYO
cemiplimab (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L01) L01XC33
Patents linked 0
Pipeline programs 91
News articles 0
Drug details — cemiplimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 91
- Data quality
- 0.89
Quick answer
cemiplimab (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN cemiplimab
Brand LIBTAYO
Mechanism Programmed cell death protein 1 inhibitor
Target Programmed cell death protein 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XC33
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Programmed cell death protein 1 inhibitor
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cemiplimab?
cemiplimab (LIBTAYO) is a programmed cell death protein 1 inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for cemiplimab?
LIBTAYO is a marketed brand name for cemiplimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.